-
公开(公告)号：US11285219B2
公开(公告)日：2022-03-29
申请号：US16745041
申请日：2020-01-16
发明人： Robert H. Zimmer , Gilles Guichard , Juliette Fremaux , Sebastien Goudreau , Claire Venin , Laura Mauran
IPC分类号： A61K47/59 , A61P3/00 , C07K7/02 , C07K14/605 , A61K38/00
摘要： The present description relates to peptidomimetic foldamers, and their synthesis. In particular, the description provides peptide-amino urea hybrid peptidomimetic foldamers comprising an alpha amino acid peptide portion and an oligourea portion.
-
公开(公告)号：US20200155637A1
公开(公告)日：2020-05-21
申请号：US16448910
申请日：2019-06-21
IPC分类号： A61K38/06 , A61K47/59 , C07K5/02 , C07K7/02 , C08G69/10 , C08G69/48 , C08L75/02 , A61K38/07 , A61K38/08
摘要： The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.
-
公开(公告)号：US20200230249A1
公开(公告)日：2020-07-23
申请号：US16745041
申请日：2020-01-16
发明人： ROBERT H. ZIMMER , Gilles Guichard , Juliette Fremaux , Sebastien Goudreau , Claire Venin , Laura Mauran
摘要： The present description relates to peptidomimetic foldamers, and their synthesis. In particular, the description provides peptide-amino urea hybrid peptidomimetic foldamers comprising an alpha amino acid peptide portion and an oligourea portion.
-
公开(公告)号：US10233213B2
公开(公告)日：2019-03-19
申请号：US15756513
申请日：2016-08-31
发明人： Gilles Guichard , Gavin W. Collie , Karolina Pulka-Ziach , Caterina Maria Lombardo , Juliette Fremaux
IPC分类号： A61K38/00 , C07K7/02 , A61K38/10 , A61K47/59 , A61K47/18 , C07C275/16 , C07D207/09 , C08L75/02
摘要： The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.
-
公开(公告)号：US20190002519A1
公开(公告)日：2019-01-03
申请号：US16023901
申请日：2018-06-29
申请人： UREKA SARL
IPC分类号： C07K14/605 , A61K47/64 , A61P3/08
摘要： The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n≥2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.
-
公开(公告)号：US20170298112A1
公开(公告)日：2017-10-19
申请号：US15491929
申请日：2017-04-19
申请人： UREKA SARL
发明人： Robert H. Zimmer , Sebastien Goudreau , Gilles Guichard , Juliette Fremaux , Claire Venin , Laura Mauran
IPC分类号： C07K14/605 , G01N33/74 , A61K38/00
摘要： The present description provides compositions and methods for producing therapeutic compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the present disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the present disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.
-
公开(公告)号：US11267861B2
公开(公告)日：2022-03-08
申请号：US15491929
申请日：2017-04-19
申请人： UREKA SARL
发明人： Robert H. Zimmer , Sebastien Goudreau , Gilles Guichard , Juliette Fremaux , Claire Venin , Laura Mauran
摘要： The present description provides compositions and methods for producing therapeutic compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the present disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the present disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.
-
公开(公告)号：US10398750B2
公开(公告)日：2019-09-03
申请号：US14465680
申请日：2014-08-21
IPC分类号： C07K7/02 , A61K38/06 , C08L75/02 , C07K5/02 , A61K38/07 , A61K38/08 , C08G69/10 , C08G69/48 , A61K47/59 , A61K38/00
摘要： The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.
-
公开(公告)号：US20210122800A1
公开(公告)日：2021-04-29
申请号：US17135627
申请日：2020-12-28
申请人： UREKA SARL
IPC分类号： C07K14/605 , A61K47/54 , A61K47/64 , A61P3/08
摘要： The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n≥2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.
-
公开(公告)号：US10889627B2
公开(公告)日：2021-01-12
申请号：US16023901
申请日：2018-06-29
申请人： UREKA SARL
摘要： The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n≥2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.025 秒)